These attributes of GLP-1 have been captured for treatment of type 2 diabetes by development of stable GLP-1 mimetics and DPPIV inhibitors which inhibit the normal rapid degradation of both incretin hormones [9]–[11]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.